There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Align Tech (ALGN – Research Report) and TriSalus Life Sciences (TLSI – Research Report) with bullish sentiments.
Invest with Confidence:
Align Tech (ALGN)
In a report released yesterday, Glen Santangelo from Jefferies maintained a Buy rating on Align Tech, with a price target of $260.00. The company’s shares closed last Thursday at $234.89.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of 6.0% and a 52.8% success rate. Santangelo covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Verrica Pharmaceuticals, and Elanco Animal Health.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Align Tech with a $258.86 average price target, implying an 11.8% upside from current levels. In a report issued on January 10, Stifel Nicolaus also maintained a Buy rating on the stock with a $275.00 price target.
See the top stocks recommended by analysts >>
TriSalus Life Sciences (TLSI)
In a report released today, Jason Wittes from Roth MKM reiterated a Buy rating on TriSalus Life Sciences, with a price target of $11.00. The company’s shares closed last Thursday at $5.16.
According to TipRanks.com, Wittes is a 4-star analyst with an average return of 7.3% and a 54.5% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Monogram Orthopaedics Inc, Chemomab Therapeutics, and Alphatec Holdings.
Currently, the analyst consensus on TriSalus Life Sciences is a Strong Buy with an average price target of $11.92, implying a 131.5% upside from current levels. In a report issued on January 10, JonesTrading also reiterated a Buy rating on the stock with a $11.00 price target.
Read More on ALGN: